Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 97-101

  Lilenbaum, R C ^a   Chen, C S ^b   Chidiac, T ^c   Schwarzenberger, P O ^d   Thant, M ^e   Versola, M ^f   Lane, S R ^f  

^a Mount Sinai Comprehensive Cancer Center   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^c Mid Ohio Oncology Hematology   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Maryland Hematol Oncol Associates   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Advanced non small cell lung cancer; Carboplatin paclitaxel; Vinorelbine gemcitabine

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FREQUENCY ANALYSIS; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STANDARDIZATION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; THROMBOCYTOPENIA;

EID: 12344334587     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi009     Document Type: Article

References (11)

1. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
2. Lilenbaum R, Herndon J, List M et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: A randomized trial of efficacy, quality of life, and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21: A-2.
3. Sederholm S. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): A Phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 2002; 21: 291a (Abstr).
4. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum based chemotherapy in advanced non-small cell lung cancer: A randomized multicenter trial. Lancet 2001; 357: 1478-1484.
5. Smit EF, Van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: A Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003; 21: 3909-3917.
6. Lilenbaum RC, Herbst RS. Vinorelbine and gemcitabine combinations in advanced non-small cell lung cancer. Clin Lung Cancer 2000; 2: 123-127.
7. Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: A Phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical trials group. J Clin Oncol 2003; 21: 3025-3034.
8. Alberola A, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 3207-3213.
9. Hollen PJ, Gralla RJ, Kris MG. Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1994; 2: 213-222.
10. Schiller JH. Platin or no platin? That is the question. J Clin Oncol 2003; 21: 3009-3010 [Editorial].
11. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 2004; 22: 254-261.